COMMUNIQUÉS West-GlobeNewswire

iSTAR Medical’s MINIject® demonstrates significant sustained 5-year efficacy in treating glaucoma in STAR-GLOBAL trial

24/04/2025 - 09:01

For immediate release iSTAR Medical’s MINIject ® demonstrates significant sustained 5-year efficacy in treating glaucoma in STAR-GLOBAL trial Five-year safety profile including corneal health confirmed and 38% IOP [...]

New survey shows that over 90% of animal owners trust and appreciate veterinary teams but underestimate the demands of the profession

24/04/2025 - 10:00

New survey data show 94% of animal owners appreciate the work of veterinarians 1 , compared to only 49% of veterinary professionals feeling their profession is appreciated, among other findings. 2 The survey confirms [...]

Composition of the Nomination Committee of Orion Corporation

24/04/2025 - 10:00

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 24 APRIL 2025 at 11.00 EEST Composition of the Nomination Committee of Orion Corporation The Board of [...]

ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

24/04/2025 - 11:00

Garching / Munich, Germany and VANCOUVER, British Columbia, April 24, 2025 – ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, and Alpha-9 Oncology (Alpha-9) , a clinical-stage [...]

RadNet, Inc. Announces Date of its First Quarter 2025 Financial Results Conference Call

24/04/2025 - 12:00

LOS ANGELES, April 24, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) , a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient [...]

Merus annonce l’acceptation de son résumé pour présentation au congrès annuel 2025 de l’ASCO®

24/04/2025 - 06:34

- Le pétosemtamab en association avec le pembrolizumab en traitement de première intention d'un CETC r/m PD-L1+ : premières données cliniques provisoires sélectionnées pour une présentation sous forme d’affiche - [...]

Addex Therapeutics to Release Full-Year 2024 Financial Results and Host Conference Call on April 25, 2025

24/04/2025 - 07:00

Geneva, Switzerland, April 24, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological [...]

[Ad hoc announcement pursuant to Art. 53 LR] Roche continues good momentum into 2025 with 6% (CER) sales growth in the first quarter

24/04/2025 - 07:00

Group sales grew by 6% 1 at constant exchange rates (CER; 7% in CHF), driven by high demand for newer medicines and diagnostic solutions. Pharmaceuticals Division sales rose by 8% (9% in CHF) on continued strong demand [...]

Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes

24/04/2025 - 07:00

Press release – No. 6 / 2025 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes The Phase 2b ZUPREME-2 trial [...]

Strong sales for Cresemba® (isavuconazole) in Japan trigger second milestone payment from Asahi Kasei Pharma to Basilea

24/04/2025 - 07:15

Allschwil, Switzerland, April 24, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal [...]

Communiqué de presse : Sanofi : forte performance au T1 et confirmation des perspectives pour 2025

24/04/2025 - 07:30

Sanofi : forte performance au T1 et confirmation des perspectives pour 2025 Paris, le 24 avril 2025 Ventes du T1 en progression de 9,7 % à TCC 1 et BNPA 2 des activités de 1,79 euro Les ventes des nouveaux lancements [...]

Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed

24/04/2025 - 07:30

Sanofi: strong Q1 performance and 2025 guidance confirmed Paris, April 24, 2025 Q1 sales growth of 9.7% at CER 1 and business EPS 2 of €1.79 Pharma launches reached sales of €0.8 billion, up 43.8%, driven by ALTUVIIIO [...]

ONWARD Medical Establishes US ADR Program and Begins Trading on OTCQX Best Market

24/04/2025 - 07:30

Sponsored Level 1 ADR program facilitates trading by US investors following recent FDA clearance and commercial launch BNY will be ADR depositary bank Ticker symbol for US investors is ONWRY EINDHOVEN, the Netherlands, [...]

Pharming Group to report first quarter 2025 financial results on May 8

24/04/2025 - 08:00

Leiden, the Netherlands, April 24, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2025 financial results, for the period [...]

Les dernières données sur l’élafibranor démontrent un profil de tolérance favorable et une efficacité significative dans la CSP, une deuxième indication dans les maladies rares du foie

24/04/2025 - 08:14

L’élafibranor a montré un profil de tolérance favorable et a démontré une efficacité en termes de relation dose-effet sur 12 semaines chez des patients atteints de CSP, une maladie rare du foie pour laquelle il n’existe [...]

Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication

24/04/2025 - 08:14

Elafibranor showed a favorable safety profile and demonstrated dose-dependent efficacy over 12 weeks for people living with PSC, a rare liver disease that currently has no approved treatment options Patients treated [...]

Bioxodes annonce des données intermédiaires positives pour son essai de phase 2a portant sur BIOX-101 dans le traitement de l’AVC hémorragique

24/04/2025 - 08:30

Le critère d’évaluation principal a été atteint, aucun événement indésirable grave associé au médicament n’a été rapporté L’évolution du volume de l’hématome et de l’œdème est favorable Le recrutement des patients a été [...]

Bioxodes announces positive Phase 2a interim data for BIOX-101 in intracerebral hemorrhagic stroke patients

24/04/2025 - 08:30

Primary endpoint met, no drug-related serious adverse events Positive hematoma and edema volume evolution Recruitment stopped early due to positive exploratory and efficacy outcomes Preparations underway to initiate [...]

Actimed Therapeutics Appoints Shaun Claydon as Chief Financial Officer

24/04/2025 - 09:00

London, UK – 24 th April 2025. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting [...]